Pancreatic Neuroendocrine Tumors
636 articles
Kerri Kaplan
Kerri Kaplan is the President of the Lustgarten Foundation, which is America’s largest private funder of pancreatic cancer research and is relentlessly focused on improving patient outcomes. Kerri oversees all aspects of the Lustgarten Foundation’s operational activities, including major fundraising initiatives, patient outreach, and the Foundation’s in-depth research portfolio. Early in her career at the […]
Testing an Approved Drug for a Specific Mutation
Researchers are testing a drug combination for melanoma in pancreatic cancer patients with a BRAF genetic mutation.
Platform Trial Design Aims to Get Information Quickly and Efficiently
Dr. Eugene Koay is leading a platform trial, for a more nimble way to adapt to participants’ response to treatments being tested.
Patients Needed for Clinical Trial/Research Study of Treatment Targeting Immune System
A clinical trial seeks pancreatic cancer patients with the MSI (microsatellite instability) genetic signature, to test an immunotherapy drug.
Using a Virus to Infect and Destroy Pancreatic Cancer Cells
A clinical trial tests the combination of standard chemotherapy plus a common cold virus that has been modified to kill cancer cells.